OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Exe

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately.

Related Keywords

Paris , France General , France , French , Nicolas Poirier , Dominique Costantini , Sylvie Berrebi David , Alexis Vandier , Thomas Guillot , Florence Portejoie , Nantes University Hospital , Linkedin , Twitter , Boehringer Ingelheim , International Media , University Of Nantes , Scientific Advisory Committee , Immunotherapy Sciences , Immunology European Center , Veloxis Pharmaceuticals Inc , University Of Louis Pasteur , Regulatory News , Chief Executive Officer , Chief Scientific Officer , European Center , Louis Pasteur , Global Management , Chief Scientific Director , Tcl Pharma , Project Manager , Non Small Cell Lung Cancer , Veloxis Pharmaceuticals , Universal Registration Document , Berrebi David Dible Eleanor Perkin , Immunotherapeutics , Ppoints , Nicolas , Poirier , Chief , Executive , Officer ,